Strides Pharma Q1 FY27 PAT up 57% YoY at Rs 165 crore

Pat Growth 25pctEbitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹1076.30

prior close

₹1066.20

announcement price

In-mkt

timing

Nifty Microcap 250market+1.1%-6.0% vs market

Pharmaceuticals peers, median of 164sector+0.1%-5.1% vs sector

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.4

15m

-0.3

30m

-4.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0+1.1-6.0+0.1-5.1

Next day

-4.8+2.4-7.3+1.1-5.9

-8.9+2.9-11.8+1.0-10.0

-10.1+4.2-14.3+1.1-11.2

-7.2+4.6-11.8+1.2-8.4

-6.9+4.6-11.5+1.5-8.4

-6.6+4.4-11.0+2.3-8.9

15d

-8.6+5.7-14.3+1.3-9.9

-4.4+6.6-10.9+2.3-6.7

+3.2+5.4-2.2+3.0+0.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Q1 FY27 consolidated revenue grew about 13 percent YoY to Rs 1,265 crore from Rs 1,120 crore. PAT jumped 57 percent YoY to Rs 165.5 crore vs Rs 105.6 crore, boosted by Rs 74.2 crore gain on Pivot Path stake dilution. EBITDA margin compressed to about 18.5 percent from 20.1 percent. Product recall costs of Rs 11 crore also recorded. Board proposed Rs 5 per share final dividend.

Likely market impact

Strong YoY profit growth aided by one-off Pivot Path gain; core margins slightly softer; dividend of Rs 5 per share positive for shareholders.